Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma

Documenti analoghi

• Concentration–QTc Analysis of Valemetostat in Patients With Hematologic Malignancies
  di: Masaya Tachibana, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma
  di: Hiroyuki Inoue, et al.
  Pubblicazione: (2025)
• Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants
  di: Masaya Tachibana, et al.
  Pubblicazione: (2025)
• Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators
  di: Akiko Watanabe, et al.
  Pubblicazione: (2025)
• Drug–Drug Interactions and Combination Therapy Strategies of Amiodarone With Digoxin, Rivaroxaban, and Phenytoin Assessed by Physiologically Based Pharmacokinetic Modeling
  di: Youjun Chen, et al.
  Pubblicazione: (2025)